Mineralys Therapeutics
MLYS
22.09
+0.14
+0.64%
Mineralys Therapeutics
US · MLYS
#2760 by market cap
Listed 2023
22.09
+0.14
+0.64%
Live - 5344 symbols - heartbeat 154s ago
· 2026-10-08 08:18
Pre-market
22.50
+1.86%
After-hours
22.38
+1.31%
Overnight
22.50
+1.86%
- Market cap
- 1.95B
- P/E (TTM)i
- -5.26
- P/Bi
- 3.54
- EPSi
- -2.29
- Div yieldi
- 0.00%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on MLYS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.6 percentage points.
Institutional ownership
- Held by institutions
- 114.37% -0.62pp
- Institutions
- 284 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund48.52%
VC/PE Fund31.73%
Hedge Fund27.76%
Public Company3.99%
Private Company1.10%
Sovereign Wealth Fund0.93%
Individual/Insider0.59%
Government Pension Fund0.33%
Top holders as of 2026-09-22
Catalys Pacific
8.82% · 7.80M sh
RA Capital Management, L.P.
8.70% · 7.69M sh
BlackRock
6.66% · 5.89M sh
Samsara BioCapital LLC
6.64% · 5.87M sh
FMR
5.10% · 4.51M sh
State Street Global Advisors
4.68% · 4.14M sh
Deerfield Management Company, L.P.
4.48% · 3.96M sh
Vanguard Capital Management, LLC
3.63% · 3.21M sh
Laurion Capital Management LP
2.83% · 2.51M sh
T. Rowe Price Group, Inc.
2.56% · 2.26M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 4 buys · 44 sells
| Name | Role | Stake |
|---|---|---|
| Jon Congleton | Chief Executive Officer | 0.52% |
| Eric Warren | Chief Commercial Officer | 0.04% |
| David Rodman | Chief Medical Officer | 0.01% |
| Daphne Karydas | Director | 0.01% |
| Adam Levy | CFO, Chief Business Officer & Secretary | 0.00% |
| Glenn Sblendorio | Director | -- |
| Srinivas Akkaraju | Independent Director | -- |
| RA Capital Management, L.P. | -- | -- |
| James Ferguson | Chief Medical Officer | -- |
| Alexander Gold | Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-29 | Jon Congleton | Chief Executive Officer | Automatic Disposition | -75,000 | $25.46 |
| 2026-09-21 | Catalys Pacific | -- | Open Market Disposition | -104,320 | $28.81 |
| 2026-09-20 | Eric Warren | Chief Commercial Officer | Derivative Exercise and Sale | -7,438 | $13.24–28.12 |
| 2026-09-16 | David Rodman | Chief Medical Officer | Intent to Sell (Form 144) | -417 | $27.95 |
| 2026-09-14 | Daphne Karydas | Director | Derivative Exercise and Sale | -3,000 | $12.02–28.58 |
| 2026-09-13 | David Rodman | Chief Medical Officer | Intent to Sell (Form 144) | -7,709 | $28.14 |
| 2026-09-08 | David Rodman | Chief Medical Officer | Intent to Sell (Form 144) | -2,171 | $30.87 |
| 2026-08-20 | Eric Warren | Chief Commercial Officer | Derivative Exercise and Sale | -7,437 | $13.24–25.98 |
| 2026-08-16 | David Rodman | Chief Medical Officer | Intent to Sell (Form 144) | -417 | $25.46 |
| 2026-08-12 | David Rodman | Chief Medical Officer | Intent to Sell (Form 144) | -14,056 | $26.48 |
| 2026-08-09 | James Ferguson | Chief Medical Officer | Other Acquisition | +102,400 | -- |
| 2026-08-09 | James Ferguson | Chief Medical Officer | Other Derivative Acquisition | +135,000 | $27.38 |
| 2026-08-09 | David Rodman | Chief Medical Officer | Derivative Exercise and Sale | -2,170 | $16.00–27.09 |
| 2026-07-20 | Eric Warren | Chief Commercial Officer | Derivative Exercise and Sale | -7,438 | $13.24–26.87 |
| 2026-07-16 | David Rodman | Chief Medical Officer | Derivative Exercise and Sale | -416 | $15.44–26.53 |
| 2026-07-14 | David Rodman | Chief Medical Officer | Automatic Disposition | -6,349 | $26.61 |
| 2026-07-12 | David Rodman | Chief Medical Officer | Intent to Sell (Form 144) | -14,058 | $27.58 |
| 2026-07-12 | David Rodman | Chief Medical Officer | Derivative Exercise and Sale | -14,058 | $1.08–27.58 |
| 2026-07-12 | Jon Congleton | Chief Executive Officer | Automatic Disposition | -10,700 | $27.24 |
| 2026-07-08 | David Rodman | Chief Medical Officer | Derivative Exercise and Sale | -2,171 | $16.00–30.30 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:18:44 · For reference only, not investment advice and not tailored to your situation.